Enhancing the therapeutic activity of an immune checkpoint inhibitor

A method of treating cancer in a subject comprising,

• identifying a subject that has been diagnosed with cancer;
• administering an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor comprises a PD-1 antibody;
• and
• administering an antagonist of denatured collagen or an antigen-binding fragment thereof, wherein the antagonist of denatured collagen comprises an antagonist of the XL313 cryptic collagen epitope, wherein the antagonist comprises the XL313 monoclonal antibody deposited with ATCC accession number PTA-6552, wherein the XL313 monoclonal antibody binds a cryptic RGDKGE (SEQ ID NO. 1) containing collagen epitope, and
• thereby treating cancer in said subject.